2025 Convergence Forum Fellows

Last May Roivant Social Ventures (RSV) launched our inaugural Convergence Forum Fellowships in support of CEOs championing healthcare equity through the development of therapeutics and technology.

We are excited to share that Roivant Social Ventures’ 2025 Convergence Fellows are:

• Spring Behrouz, PhD, CEO of Vincere Bioscience

• Feyisayo Eweje, PhD, Co-Founder of Procure Bio and MD Candidate at Harvard Medical School

The Convergence Forum for Leaders in Healthcare Innovation is an invitation only annual event that explores what’s happening in the rapidly-converging worlds of biotech, pharma, healthcare, medical devices, and the Internet. The programs foster debate and discussion while providing an opportunity for participants to make important new contacts, explore new directions in research, and delve deeply into what it takes to maintain competitive advantage in a fast-changing world.

Spring Behrouz, PhD
CEO, Vincere Bioscience
PhD in Neuroscience from Michigan State University Postdoctoral work at Mayo Clinic

Vincere Biosciences is dedicated to conquering age-related diseases through the development of small molecule therapeutics empowered by a suite of computational tools alongside traditional biology and drug discovery expertise. Vincere focuses on developing small molecules that enhance the removal of damaged mitochondria by modulating mitochondrial quality control mechanisms, such as mitophagy. These small molecules have the potential to become the world's first-ever medicines capable of slowing down or even halting the progression of debilitating conditions like Parkinson's disease and other age-related diseases.

Behrouz has spent over 15 years working on Parkinson's disease. In 2014 she founded NeuroInitiative, where her team is creating a computer simulation software for scientists to observe and manipulate molecular interactions that occur inside brain cells. This empowers researchers to perform virtual experiments before going into the laboratory, reducing the timeline and cost and increasing the likelihood of successful therapeutic drugs. Building on the wealth of scientific knowledge accumulated in recent years, NeuroInitiative brings this data to life with biologically accurate simulations, rich 3D visualizations, and the ability to interact directly with the molecules in the system. The focus and immediate impact of this software, is that researchers can unravel therapeutic targets and shorten research timelines.

Behrouz’ vision applying advanced computational drug discovery methods at NeuroInitiative led to the creation of Vincere Bioscience. She is currently CEO of both companies.

Previously Behrouz worked with Matt Farrer at Mayo clinic to characterize genetic models of Parkinson's disease and was part of the team that discovered a new pathogenic mutation in VPS35. Her PhD work implemented cutting edge laser capture, microarray, and in vivo siRNA techniques to identify protective genomic changes in Parkinson’s models. Behrouz is the recipient of JBJ’s 40 under 40 award and winner of One Spark’s science award.

Feyisayo Eweje, PhD 
Co-Founder, Procure Bio
MD Candidate at Harvard Medical School
PhD in Health Sciences & Technology Medical Engineering and Medical Physics from MIT 
NIH NRSA Predoctoral Fellow

Eweje is developing new technologies for delivering RNA and protein therapies and recently completed his PhD in Medical Engineering through the Harvard-MIT Program in Health Sciences and Technology.  During his doctoral studies, he conducted research in the lab of Dr. Elliot Chaik at Beth Israel Deaconess Medical Center, focusing on the design of non-viral, protein-based nanoparticles for the targeted delivery of nucleic acid and protein therapeutics. This work forms the foundation of Procure Bio, a company he co-founded to advance these delivery systems for in vivo gene editing, with a focus on cystic fibrosis and delivery to the lungs, as well as inherited blood disorders. This latter direction aims to enable gene editing-based treatments without the need for the high-dose chemotherapy or myeloablation that patients with inherited blood disorders currently endure.

Eweje explains, “Protein materials, particularly human-derived protein materials, are far less likely to trigger immune responses, which is one major advantage.” He adds, “The other thing that we’re actively working towards in the lab is leveraging the programmability and precise structure of recombinant proteins. We’re exploring applications ranging from gene editing in the lungs to immunotherapy and novel approaches to cancer treatment.”

Eweje has previously served Co-VP of Clinical Operations at Nucleate and Co-Managing Director at the Critical Healthcare Information Integration Network (CHIIN), and is a Co-Founder and teacher at the Program of Ragon and IMES in Science and Medicine (PRISM).

The Critical Healthcare Information Integration Network (CHIIN) is a nonprofit that provides medical information to community health workers in rural and underdeveloped areas of Africa. It operates via a chatbot that can respond to queries over SMS text messaging and is therefore able to reach communities without internet access, indirectly assisting thousands of patients.

Nucleate is a free, trainee-led 501(c)(3) non-profit organization dedicated to empowering the next generation of biotech leaders. As a global organization, we democratize biotech education, spark new intellectual communities, and build bridges within and across ecosystems by providing open-access programming, events and resources.

The Program of Ragon and IMES in Science and Medicine (PRISM) hosts weekly programs for high school students in the greater Boston area to learn directly from scientists and clinicians about various topics in STEM.